FDA Approves Merck’s Infant RSV Antibody Enflonsia, as Prevention Options Enter a New Round of Competition

Respiratory syncytial virus (RSV) causes only brief discomfort for most adults, but in recently born infants it can quickly become a risk of wheezing, hypoxia, and hospitalization. The U.S. Food and Drug Administration (FDA) approval of Merck’s Enflonsia (clesrovimab-cfor) means that another long-acting antibody has been added to the U.S. infant RSV prevention market, rather than waiting to manage the disease course after infection occurs.

According to Merck’s announcement and the FDA label, Enflonsia is indicated for newborns and infants born during RSV season, or those who are about to enter their first RSV season, to prevent lower respiratory tract disease caused by RSV. The product is administered by intramuscular injection, and the recommended dose is a single 105 mg prefilled syringe; this fixed-dose design may make clinical scheduling more straightforward than regimens adjusted by body weight, but real-world execution will still depend on medical institution workflows and insurance coverage.

The key evidence listed in the FDA label comes from Trial 004, a placebo-controlled Phase 2b/3 trial that enrolled infants with a gestational age of more than 29 weeks, from birth to under 1 year of age, who were about to enter their first RSV season. The label shows that 2,411 infants received Enflonsia and 1,203 received placebo; within 150 days after dosing, Enflonsia had protective efficacy of 60.5% against RSV-associated lower respiratory tract infection requiring medical attention, and protective efficacy of 84.3% against RSV-associated hospitalization.

Another study, Trial 007, compared Enflonsia with palivizumab. The study population included premature infants with a gestational age of 35 weeks or less, or high-risk infants with chronic lung disease of prematurity, hemodynamically significant congenital heart disease, and other conditions. According to the FDA label, among 446 participants who received Enflonsia and 450 who received palivizumab, rates of RSV-associated medically attended lower respiratory tract infection and hospitalization within 150 days were broadly similar; this provides a reference point for high-risk groups, but it is not equivalent to a direct superiority comparison across all infant populations.

On safety, the common adverse reactions listed in the FDA label include injection-site erythema, injection-site swelling, and rash. Because the public information mainly comes from the approval announcement, the label, and clinical trial registration information, rare adverse events, real-world performance after administration in different healthcare settings, and coordination with other RSV prevention strategies still need to be supplemented by post-marketing surveillance and real-world data.

After approval, policy adoption will determine whether the product can truly enter routine pediatric care. Verywell Health reported that a U.S. Centers for Disease Control and Prevention (CDC) advisory group subsequently voted 5 to 2 in support of recommending Enflonsia for infants under 8 months of age who are born during or entering their first RSV season; the report also said advisers unanimously supported including clesrovimab in the Vaccines for Children program, and that the work group analysis did not prefer clesrovimab or nirsevimab among eligible infants.

The significance of this approval is not only that another antibody is available. RSV prevention has been moving from a seasonal medication used for a small number of high-risk infants toward broader protection for newborns and infants; next, clinicians will need to make clear arrangements among maternal RSV vaccines, infant long-acting antibodies, supply timelines, and family access. For parents, the most important message is therefore more concrete: prevention options are increasing, but when they should be used, by whom, and for which infant should still be judged according to individual risk and local vaccination recommendations.